Wedbush Comments on Chimerix, Inc.’s Q1 2025 Earnings (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Equities research analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Chimerix in a research report issued to clients and investors on Wednesday, May 1st. Wedbush analyst D. Nierengarten forecasts that the biopharmaceutical company will earn ($0.23) per share for the quarter. Wedbush currently has a “Outperform” rating and a $6.00 price target on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.77) per share. Wedbush also issued estimates for Chimerix’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.24) EPS and Q4 2025 earnings at ($0.23) EPS.

A number of other equities research analysts have also issued reports on CMRX. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Chimerix in a research report on Friday, March 1st. StockNews.com downgraded Chimerix from a “hold” rating to a “sell” rating in a research note on Friday.

Chimerix Price Performance

NASDAQ:CMRX opened at $0.95 on Friday. The company has a market capitalization of $85.41 million, a P/E ratio of -1.02 and a beta of 1.13. Chimerix has a 52 week low of $0.88 and a 52 week high of $1.57. The stock’s fifty day moving average is $1.04 and its two-hundred day moving average is $1.00.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 39.62%. During the same quarter last year, the company posted ($0.24) earnings per share.

Institutional Investors Weigh In On Chimerix

Institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its stake in shares of Chimerix by 17.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock valued at $481,000 after acquiring an additional 72,719 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Chimerix by 190.0% during the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 387,638 shares in the last quarter. Vance Wealth Inc. purchased a new position in shares of Chimerix in the fourth quarter valued at $46,000. Pale Fire Capital SE acquired a new stake in Chimerix during the 3rd quarter valued at $95,000. Finally, RA Capital Management L.P. purchased a new stake in Chimerix during the 3rd quarter worth $6,240,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.